BSE: 543520 | NSE: | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Global Longlife Hospital and Research Ltd is a average quality company.
The key valuation ratios of Global Longlife Hospital and Research Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Global Longlife Hospital and Research Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 12.1% | 3.7% | 13.5% | 29.4% | 6.7% | -2.7% | - |
| Value Creation Index ⓘ | -0.1 | -0.7 | 0.0 | 1.1 | -0.5 | -1.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||
| Sales ⓘ | 34.5 | 33.5 | 32.7 | 32.8 | 23.5 | 13.5 | 14 |
| Sales YoY Gr. | - | -2.9% | -2.5% | 0.4% | -28.4% | -42.5% | - |
| Adj EPS ⓘ | 2 | -1.2 | 2.9 | 5.2 | 1.7 | -2.1 | -2.1 |
| YoY Gr. | - | -163.1% | NA | 77.1% | -66.3% | -217.8% | - |
| BVPS (₹) ⓘ | 0 | 0 | 14.5 | 20 | 58.9 | 22.6 | 22.6 |
| Adj Net Profit ⓘ | 1.4 | -0.9 | 2.1 | 3.6 | 1.8 | -2.2 | -2 |
| Cash Flow from Ops. ⓘ | 5.4 | 3.9 | 6.9 | 9.4 | -40.4 | -5.1 | - |
| Debt/CF from Ops. ⓘ | 5 | 6 | 2.5 | 0.9 | -0.2 | -2.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | -17.1% | -25.5% | -42.5% | ||||
| Adj EPS ⓘ | NA | -201% | -188.9% | -217.8% | ||||
| BVPSⓘ | NA | NA | 16.1% | -61.6% | ||||
| Share Price | - | - | - | -15% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 11.1 | -7.2 | 16.3 | 23.6 | 4.5 | -4.8 | -9.2 |
| Op. Profit Mgn % ⓘ | 19.5 | 10.1 | 16.6 | 25.3 | 17.3 | -1.7 | NAN |
| Net Profit Mgn % ⓘ | 4 | -2.6 | 6.3 | 11 | 7.8 | -15.9 | -16.2 |
| Debt to Equity ⓘ | 2.2 | 2.1 | 1.7 | 0.6 | 0.2 | 0.5 | - |
| Working Cap Days ⓘ | 0 | 206 | 165 | 125 | 478 | 942 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 56 | 33 | 43 | 103 | 121 | 0 |
No data to display
Return on Equity is Poor
Sales growth has been subdued in last 3 years -25.52%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -2.1 | - |
| TTM Sales (₹ Cr.) | 13.5 | - |
| BVPS (₹.) ⓘ | 22.6 | - |
| Reserves (₹ Cr.) ⓘ | 15 | - |
| P/BV ⓘ | 1.41 | - |
| PE ⓘ | 0.00 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 27.00 / 61.70 |
| All Time Low / High (₹) | 27.00 / 141.10 |
| Market Cap (₹ Cr.) | 33.6 |
| Equity (₹ Cr.) | 10.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 40.5 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Sales | 34.54 | 33.54 | 32.70 | 32.82 | 23.50 | 13.51 |
| Operating Expenses ⓘ | 27.79 | 30.16 | 27.27 | 24.58 | 19.43 | 13.80 |
| Manufacturing Costs | 15.12 | 19.52 | 13.52 | 14.21 | 9.71 | 7.83 |
| Material Costs | 4.34 | 5.06 | 8.59 | 3.60 | 4.33 | 1.22 |
| Employee Cost | 4.28 | 4.06 | 3.42 | 3.52 | 3.03 | 2.74 |
| Other Costs ⓘ | 4.05 | 1.51 | 1.74 | 3.25 | 2.36 | 2.01 |
| Operating Profit ⓘ | 6.75 | 3.39 | 5.44 | 8.23 | 4.07 | -0.28 |
| Operating Profit Margin (%) | 19.5% | 10.1% | 16.6% | 25.1% | 17.3% | -2.1% |
| Other Income ⓘ | 0.19 | 0.11 | 0.06 | 0.23 | 0.24 | 0.06 |
| Interest ⓘ | 2.09 | 2.44 | 2.43 | 1.61 | 0.43 | 0.80 |
| Depreciation ⓘ | 2.15 | 2.13 | 1.31 | 1.14 | 1.17 | 1.25 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 2.69 | -1.06 | 1.76 | 5.71 | 2.71 | -2.27 |
| Tax ⓘ | 1.32 | -0.20 | -0.29 | 2.14 | 0.88 | -0.08 |
| Profit After Tax | 1.36 | -0.86 | 2.05 | 3.57 | 1.83 | -2.19 |
| PAT Margin (%) | 4.0% | -2.6% | 6.3% | 10.9% | 7.8% | -16.2% |
| Adjusted EPS (₹) | 2.0 | -1.2 | 2.9 | 5.1 | 1.7 | -2.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 12.35 | 11.49 | 13.68 | 16.96 | 64.29 | 25.93 | ||||
| Share Capital ⓘ | 7 | 7 | 7 | 7 | 10.50 | 10.50 | ||||
| Reserves ⓘ | 5.35 | 4.49 | 6.68 | 9.96 | 53.79 | 15.43 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Debt | 23.55 | 22.91 | 15.32 | -0.99 | 9.14 | 11.78 | ||||
| Long Term Debt | 17.72 | 16.89 | 12.51 | 2.82 | 3.64 | 3.41 | ||||
| Short Term Debt | 5.83 | 6.03 | 2.81 | -3.81 | 5.50 | 8.37 | ||||
| Trade Payables | 2.74 | 5.43 | 3.26 | 4.28 | 1.31 | 2.56 | ||||
| Others Liabilities ⓘ | 1.47 | -1.30 | 0.76 | 11.15 | -0.95 | -0.76 | ||||
| Total Liabilities ⓘ | 40.12 | 38.53 | 33.02 | 31.40 | 73.79 | 39.51 | ||||
Fixed Assets | ||||||||||
| Gross Block | 21.74 | 20.27 | 25.74 | 26.14 | 27.11 | 29.02 | ||||
| Accumulated Depreciation | 1.58 | 1.55 | 8.28 | 9.42 | 10.59 | 11.75 | ||||
| Net Fixed Assetsⓘ | 20.17 | 18.72 | 17.46 | 16.71 | 16.52 | 17.27 | ||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 1.03 | 0 | ||||
| Investmentsⓘ | 0.10 | 0.10 | 0.47 | 0.10 | 0.10 | 0.03 | ||||
| Inventories | 2.02 | 2.19 | 0.81 | 0.88 | 0.82 | 0.44 | ||||
| Trade Receivables | 8.69 | 6.27 | 7.84 | 8.91 | 9.70 | 1.95 | ||||
| Cash Equivalents | 0.48 | 1.29 | 0.44 | 0.22 | 3.60 | 0.39 | ||||
| Others Assetsⓘ | 8.66 | 9.96 | 6 | 4.58 | 42.03 | 19.44 | ||||
| Total Assets ⓘ | 40.12 | 38.53 | 33.02 | 31.40 | 73.79 | 39.51 | ||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 5.40 | 3.90 | 6.88 | 9.42 | -40.42 | -5.07 |
| PBT ⓘ | 2.69 | -1.06 | 1.76 | 5.71 | 2.71 | -2.27 |
| Adjustment ⓘ | 4.16 | 4.47 | 4.10 | 2.89 | 2.02 | -33.58 |
| Changes in Working Capital ⓘ | -1.44 | 0.49 | 1.02 | 0.16 | -43.87 | 30.87 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0.67 | -1.27 | -0.10 |
| Cash Flow From Investing Activity ⓘ | -0.33 | -0.04 | 0.02 | 0.01 | -1.90 | -0.82 |
| Capex | -0.40 | -0.11 | -0.04 | -0.46 | -2 | -1.03 |
| Net Investments | 0 | 0 | 0 | 0.27 | -0.02 | 0.15 |
| Others ⓘ | 0.07 | 0.07 | 0.06 | 0.20 | 0.12 | 0.06 |
| Cash Flow From Financing Activityⓘ | -4.77 | -3.05 | -7.22 | -9.66 | 45.70 | 2.67 |
| Net Proceeds from Shares ⓘ | 2 | 0 | 0 | 0 | 45.50 | 0 |
| Net Proceeds from Borrowing ⓘ | -3.44 | -0.83 | -4.94 | -9.69 | 0.82 | -0.23 |
| Interest Paid ⓘ | -2.07 | -2.41 | -2.28 | -1.31 | -0.40 | -0.77 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | -1.26 | 0.19 | 0 | 1.34 | -0.22 | 3.67 |
| Net Cash Flow ⓘ | 0.31 | 0.81 | -0.33 | -0.22 | 3.38 | -3.22 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 11.05 | -7.23 | 18.94 | 29.65 | 4.82 | -5.11 | ||||
| ROCE (%) | 12.09 | 3.69 | 13.49 | 29.36 | 6.69 | -2.73 | ||||
| Asset Turnover Ratio | 0.86 | 0.85 | 0.91 | 1.02 | 0.45 | 0.24 | ||||
| PAT to CFO Conversion(x) | 3.97 | N/A | 3.36 | 2.64 | -22.09 | N/A | Working Capital Days | |||
| Receivable Days | 92 | 81 | 79 | 93 | 144 | 157 | ||||
| Inventory Days | 21 | 23 | 17 | 9 | 13 | 17 | ||||
| Payable Days | 231 | 295 | 185 | 382 | 235 | 579 | ||||
Global Longlife Hospital and Research is known as a Multi Speciality Tertiary Care Hospital of Gujarat with many beds well equipped for Medical & Surgical Specialities. It provides platform to the doctors for treatment of their patients. The company has adopted the Standard Operating Procedures (SOPs) given by Ministry of Health & Family Welfare. Under the said SOPs every work function of its hospital is defined, every process is written down and every employee is trained in his/her duties as soon as he/she joins. Every equipment is maintained as per a predefined schedule. Every necessary license is obtained and renewed as required time to time. The company is certified by National Accreditation Board for Hospitals and Healthcare Providers (NABH Accredited) which is committed to support improvement of quality of healthcare service in its country for all strata of the population through various methodologies and tools to supplement the efforts of the providers of healthcare service and the requirements of the system at various levels. The main purpose of the company’s promoter is to serve the people, hence, the company is also following the same path for which it put its ethics above the all cost. Through the Mukhya Mantri Amrutum Yojana the company has served over 6,000 patients up till now.
The company has invested in, and have established a IT system both for clinical purposes as well as integrating systems and processes through HMS (Hospital Management System)which includes Central Registration module, Appointment, Barcode Generation, Case Paper Generation, OPD Billing, Procedure billing, IPD Registration, Advance & Refund, Due billing, TPA/Package Billing, User Management, Doctor Sharing, Software Security, Management Reports, Discharge Summary towards streamlining its clinical and administrative functions. It has adopted technology with a view to ensure quick transmission of disease data, subsequent analysis, and prompt disease management.
Business area of the company
The company provides health care services. The company offers Oncology, Ophthalmology, Cardiology, Dermatology, Gynecology, Spine Surgery, Plastic Surgery, Ultrasound, Microbiology, Dialysis, and Physiotherapy among other healthcare services. Global Longlife Hospital is certified by the National Accreditation Board for Hospitals and Healthcare Providers (NABH Accredited).
Major Events, Key Awards, Accreditations or Recognition
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
